Hydroxyurea (also known as hydroxyurea) is an antineoplastic antimetabolite used in treatment protocols for chronic myeloproliferative disorders, and in the management of sickle cell disease.

**General description**

Hydroxyurea (also known as hydroxyurea) is an antineoplastic antimetabolite used in treatment protocols for chronic myeloproliferative disorders, and in the management of sickle cell disease.

**Recommendations**

**Section** | **Cytotoxic medicines**
---|---
Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

**Indications**

- [Chronic myeloid leukaemia, not elsewhere classified](#)
- Squamous cell carcinoma of oropharynx

**Section** | **Other medicines for haemoglobinopathies**
---|---
Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

**Indications**

- Other specified sickle cell disorders or other haemoglobinopathies